Coverage of Intravenous Immunoglobulin for Autoimmune Blistering Diseases Among US Insurers.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28813559.
- Also identified by DOI 10.1001/jamadermatol.2017.2614 and PMC identifier 5817455.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this study, the authors examine coverage for IVIG to treat autoimmune blistering diseases by public and private insurers in the United States.
Medical subject headings
- Autoimmune Diseases
- Immunoglobulins, Intravenous
- Insurance Carriers
- Skin Diseases, Vesiculobullous